BUDGET IMPACT ANALYIS OF MECHANICHAL THROMBECTOMY IN THE TREATMENT OF ACUTE ISCHEMUC STROKE

Author(s)

Sika K1, Peirone V2, Soilly AL3, Bocquet A2
1Fondation Ophtalmologique Adolphe de Rothschild, Paris19, 75, France, 2Stryker, Levallois-Perret, France, 3CHU Bourgogne, DRCI, USMR,F-21000, Dijon, France

OBJECTIVES: The introduction of Mechanical Thrombectomy (MT) techniques in the treatment of Acute Ischemic Stroke (AIS) has raised the question of the cost of these technologies for payers. This study assessed the budgetary impact (BI) of MT with Stent Retriever (SR) in combination with intravenous thrombolysis (IVT) compared to IVT alone in the treatment of AIS in France.

METHODS: A BI model was developed to estimate medical and non-medical costs of the combined strategy (MT with SR+IVT) compared to IVT alone over a five-year period on a Health Insurance (HI) perspective. MT activity was estimated based on the volumes of the previous years at a national level. Efficacy data were collected from the Hermès meta-analysis study. Medical costs were taken from the rate base of the HI and existing literature on cost of stroke in France. Non-medical costs as disability pension, daily sick pay, and constant attendance allowance, were collected from the French HI website and were estimated according to the level of disability. A discount rate of 4% was applied. Costs were expressed in 2017 euros. The analysis was done on Excel, 2010.

RESULTS: A total of 21,121 MT were estimated. The annual BI was €12,282,024, €10,976,441, €2,946,268, -€6,719,116, and -€18,059,361 respectively from the 1st to the 5th year. 5-years BI was estimated at € 1,426,256 with a net benefit starting the 4th year. Disability pension, daily sick pay, constant attendance allowance and follow-up medical costs were lower in the combined strategy (MT with SR+IVT). Sensitivity analysis showed that follow up medical cost was the most influential parameter on the BI.

CONCLUSIONS: This study shows that the adoption of the combined strategy (MT with SR+IVT) generates economic benefit for the French Health Insurance due to the reduction of follow-up medical costs and non-medical costs associated to disability.

Conference/Value in Health Info

2018-11, ISPOR Europe 2018, Barcelona, Spain

Value in Health, Vol. 21, S3 (October 2018)

Code

PMD29

Topic

Economic Evaluation

Topic Subcategory

Budget Impact Analysis

Disease

Cardiovascular Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×